Kemi M Doll1,2,3, Ke Meng3, Ethan M Basch3, Paola A Gehrig1,3, Wendy R Brewster1,3, Anne-Marie Meyer3. 1. Division of Gynecologic Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina. 2. Division of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Adults aged ≥65 years who are dually enrolled in Medicare and Medicaid are an at-risk group in health care. However, to the best of the authors' knowledge, the outcomes of women with gynecologic cancers in this population are unknown. METHODS: The current study was a population-based cohort study of North Carolina state cancer registry cases of uterine, ovarian, cervical, and vulvar/vaginal cancers (2003-2009), with linked enrollment in Medicare and state Medicaid. Outcomes of all-cause mortality and stage of disease at the time of diagnosis were analyzed as a function of enrollment status using multivariate analysis and survival curves. RESULTS: Of 4522 women aged ≥65 years (3702 of whom were enrolled in Medicare [82%] and 820 of whom were dually enrolled [18%]), there were 2286 cases of uterine (51%), 1587 cases of ovarian (35%), 302 cases of cervical (7%), and 347 cases of vulvar/vaginal (8%) cancers. Dual enrollees had increased all-cause mortality overall (adjusted hazard ratio [aHR], 1.34; 95% confidence interval [95% CI], 1.19-1.49), and within each cancer site (uterine: aHR, 1.22 [95% CI, 1.02-1.47]; ovarian: aHR, 1.25 [95% CI, 1.05-1.49]; cervical: aHR, 1.34 [95% CI, 0.96-1.87]; and vulvar/vaginal: aHR, 1.93 [95% CI, 1.36-2.72]). Increased odds of advanced-stage disease at the time of diagnosis among dual enrollees was only present in patients with uterine cancer (adjusted odds ratio, 1.38; 95% CI, 1.06-1.79). Stratified survival curves demonstrated the strongest disparities among women with early-stage uterine and early-stage vulvar/vaginal cancers. CONCLUSIONS: Women aged ≥65 years who were dually enrolled in Medicare and Medicaid were found to have an overall 34% increase in all-cause mortality after diagnosis with a gynecologic cancer compared with the non-dually enrolled Medicare population. Women with early-stage uterine and vulvar/vaginal cancers appeared to have the most disparate outcomes. Because these malignancies are generally curable, they have the most potential for benefit from targeted interventions.
BACKGROUND: Adults aged ≥65 years who are dually enrolled in Medicare and Medicaid are an at-risk group in health care. However, to the best of the authors' knowledge, the outcomes of women with gynecologic cancers in this population are unknown. METHODS: The current study was a population-based cohort study of North Carolina state cancer registry cases of uterine, ovarian, cervical, and vulvar/vaginal cancers (2003-2009), with linked enrollment in Medicare and state Medicaid. Outcomes of all-cause mortality and stage of disease at the time of diagnosis were analyzed as a function of enrollment status using multivariate analysis and survival curves. RESULTS: Of 4522 women aged ≥65 years (3702 of whom were enrolled in Medicare [82%] and 820 of whom were dually enrolled [18%]), there were 2286 cases of uterine (51%), 1587 cases of ovarian (35%), 302 cases of cervical (7%), and 347 cases of vulvar/vaginal (8%) cancers. Dual enrollees had increased all-cause mortality overall (adjusted hazard ratio [aHR], 1.34; 95% confidence interval [95% CI], 1.19-1.49), and within each cancer site (uterine: aHR, 1.22 [95% CI, 1.02-1.47]; ovarian: aHR, 1.25 [95% CI, 1.05-1.49]; cervical: aHR, 1.34 [95% CI, 0.96-1.87]; and vulvar/vaginal: aHR, 1.93 [95% CI, 1.36-2.72]). Increased odds of advanced-stage disease at the time of diagnosis among dual enrollees was only present in patients with uterine cancer (adjusted odds ratio, 1.38; 95% CI, 1.06-1.79). Stratified survival curves demonstrated the strongest disparities among women with early-stage uterine and early-stage vulvar/vaginal cancers. CONCLUSIONS:Women aged ≥65 years who were dually enrolled in Medicare and Medicaid were found to have an overall 34% increase in all-cause mortality after diagnosis with a gynecologic cancer compared with the non-dually enrolled Medicare population. Women with early-stage uterine and vulvar/vaginal cancers appeared to have the most disparate outcomes. Because these malignancies are generally curable, they have the most potential for benefit from targeted interventions.
Authors: Jason D Wright; Sharyn N Lewin; Israel Deutsch; William M Burke; Xuming Sun; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: Gynecol Oncol Date: 2011-09-28 Impact factor: 5.482
Authors: Jason D Wright; Sharyn N Lewin; Nicanor I Barrena Medel; Xuming Sun; William M Burke; Israel Deutsch; Thomas J Herzog Journal: Gynecol Oncol Date: 2011-03-22 Impact factor: 5.482
Authors: Pauline T Truong; Hosam A Kader; Barbara Lacy; Mary Lesperance; Mary V MacNeil; Eric Berthelet; Elissa McMurtrie; Skaria Alexander Journal: Am J Clin Oncol Date: 2005-04 Impact factor: 2.339
Authors: Terri Madison; David Schottenfeld; Sherman A James; Ann G Schwartz; Stephen B Gruber Journal: Am J Public Health Date: 2004-12 Impact factor: 9.308
Authors: Lisa M Lines; Julia Cohen; Michael T Halpern; Ashley Wilder Smith; Erin E Kent Journal: Cancer Causes Control Date: 2019-08-17 Impact factor: 2.506
Authors: Stephanie Cham; Ling Chen; William M Burke; June Y Hou; Ana I Tergas; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Obstet Gynecol Date: 2016-10 Impact factor: 7.661
Authors: Tomi F Akinyemiju; Lauren E Wilson; Nicole Diaz; Anjali Gupta; Bin Huang; Maria Pisu; April Deveaux; Margaret Liang; Rebecca A Previs; Haley A Moss; Ashwini Joshi; Kevin C Ward; Maria J Schymura; Andrew Berchuck; Arnold L Potosky Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Adewole S Adamson; Lei Zhou; Christopher D Baggett; Nancy E Thomas; Anne-Marie Meyer Journal: JAMA Dermatol Date: 2017-11-01 Impact factor: 10.282
Authors: En Cheng; Pamela R Soulos; Melinda L Irwin; Elizabeth M Cespedes Feliciano; Carolyn J Presley; Charles S Fuchs; Jeffrey A Meyerhardt; Cary P Gross Journal: JAMA Netw Open Date: 2021-12-01
Authors: Carlos Sanhueza; Joaquín Araos; Luciano Naranjo; Eric Barros; Mario Subiabre; Fernando Toledo; Jaime Gutiérrez; Delia I Chiarello; Fabián Pardo; Andrea Leiva; Luis Sobrevia Journal: J Cell Mol Med Date: 2016-07-29 Impact factor: 5.310